The pharmaceutical company doubles its production capacity and will modernize digital and manufacturing systems. Read
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The company is expanding its production facilities in Europe. It will allocate over €100 million to the acquired plant in Spain, and approximately PLN 700 million to investments in Poland by 2030. A key project will be the inhalation medication factory in Pabianice.